Steroids have long been used to improve a number of clinical conditions because of their role in reducing inflammatory responses, but their use has always been limited because of their possible longterm side effects. The aim of this review is to establish whether steroids can have a positive effect on the outcome of some pediatric upper respiratory tract infections. We used PubMed to select all ofthe studies on topical or systemic steroids, and their therapeutic use in children with rhinosinusitis (RS), acute otitis media (AOM), otitis media with effusion (OME), acute pharyngitis (AP), or periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA), published over the last 15 years. Although a generally significant improvement in signs and symptoms has been observed with the use of intranasal steroids in children with RS, it is not clear which molecule should be recommended, how long treatment should be continued, or whether the benefits are limited to allergic children. No high-quality studies on the use of topical or systemic steroids in AOM have been carried out, and the results of studies of OME are controversial. The potential positive effects of steroids in children with AP are too slight to justify their use, and their possible adverse effects (particularly in the case of repeated administration) have not been clearly evaluated. Oral corticosteroids seem to be effective in resolving the symptoms of PFAPA, although they do not prevent future fever cycles. These findings show that further randomised and controlled studies are required in order to approach upper respiratory tract infections correctly and avoid the risks associated with frequent steroid use.
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Steroids have long been used to improve a number ofclinical conditions because oftheir role in reducing inflammatory responses (l). Inflammation is a natural host response to an infection, but an excessive response can worsen the clinical condition. Steroids act by switching off multiple inflammatory genes, such as those regulating the secretion of cytokines, chemokines, adhesion molecules and inflammatory enzymes, activating a number of anti-inflammatory genes, and increasing the degradation of the mRNA encoding certain inflammatory proteins (2) .
However, the use of systemic steroids has always been limited by the fact that their prolonged use has been associated with the development of osteoporosis (3, 4) , retarded growth (5), behavioural changes (6) , and suppression of the hypothalamicpituitary-adrenal axis (7) . Furthermore, although topical steroids seem to be usually safe and only associated with epistaxis and headache (8) , it has been recently suggested that they may also interfere with growth (9) . Upper respiratory tract infections are extremely common, especially in children, and steroids are frequently prescribed in some countries in order to relieve symptoms and reduce their duration. The aim ofthis review is to establish whether steroids can have a positive effect on the outcome of some pediatric upper respiratory tract infections. We used PubMed to select all of the studies on topical or systemic steroids and their therapeutic use in children with rhinosinusitis (RS), acute otitis media (AOM), otitis media with effusion (OME), acute pharyngitis (AP), or periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) that have been published over the last 15 years. More than 1,500 articles were identified, but we only considered those published in English, related to children and adolescents, and containing evidence-based data or describing recommendations from scientific societies.
RHINOSINUSITIS (RS)
Rhinosinusitis is inflammation of the paranasal sinuses and is classified on the basis of symptom duration into acute «30 days), subacute (30-90 days) and chronic forms (>90 days) (10) . It is mainly treated using antibiotics, but there are various adjuvant therapies that can be administered to improve symptoms (10), including the use of systemic or topical (i.e. intranasal) steroid treatment. Table I summarises some of the pediatric studies that have evaluated the efficacy of systemic or topical steroids in treating RS. Four of the eight studies were carried out by the same group ofauthors (11, 14, 16, 18) , four included children in the first years oflife (12, 13, 15, 17) , six considered acute RS (11-14, 16, 18) , and two chronic RS (IS, 17). Various treatment schedules were used: most of the studies compared antibiotic therapy plus an intranasal steroid (i.e. budesonide, flunisolide, fluticasone propionate, mometasone furoate) for a 7-to 21-day period with antibiotics plus placebo (11) (12) (13) (14) (15) (16) 18) , whereas one compared antibiotic therapy plus an oral corticosteroid (i.e. methylprednisolone) for 30 days with antibiotic therapy plus placebo (17) . All of the studies recorded a significantly greater improvement in nasal obstruction, post-nasal discharge and cough in the steroid-treated group (11) (12) (13) (14) (15) (16) (17) (18) . However, although some were randomised, double-blind and placebocontrolled trials, they were clearly limited by factors such as the small number ofpatients, the inclusion of allergic children, the use of different regimens, and the absence of a microbiological evaluation (so it is not possible to determine whether the unresponsive cases were due to resistant pathogens).
The multidisciplinary expert panel of the Infectious Diseases Society of America has recently recommended intranasal steroids as an adjunct to antibiotics in all patients with RS, regardless of age and the duration of symptoms, and highlighted the fact that major benefits can be observed in those with a history ofallergic rhinitis (19) . In our opinion, there is not enough evidence to recommend intranasal or oral steroids systematically in children with RS, and further data are required to confirm their usefulness, define the recommended schedule, and clarify which pediatric population(s) may benefit from their use.
ACUTE OTITIS MEDIA (AOM) AND OTITIS MEDIA WITH EFFUSION (OME)
Although the incidence of AOM has been significantly reduced by the widespread use of vaccines against its possible causative pathogens (20) , it remains one of the most common infectious diseases of childhood and almost all children experience at least one episode in the first three years of life. AOM is considered a bacterial disease that is mainly due to Streptococcus pneumoniae and untypeable Haemophilus injluenzae (21) . Given its etiology, the only effective primary treatment is antibiotic administration. However, one consequence of antibiotic therapy is bacterial death and the release of inflammatory bacterial products (i.e. lipopolysaccharides, peptidoglycans) that can exacerbate and prolong inflammation in the middle ear, thus leading to OME and further episodes of AOM (22) . For these reasons, some authors have considered the use of steroids in the treatment of pediatric AOM and OME (Table II) .
Only one study (carried out about 10 years ago) evaluated the impact of systemic corticosteroids on the course ofAOM (23). Chonmaitree et al. enrolled 179 children with AOM who were treated with one intramuscular dose of ceftriaxone and then assigned to receive prednisolone (2 mg/kg/day) or placebo for five days. The only (clinically marginal) advantage of systemic corticosteroid treatment was a higher frequency of temporarily normalised tympanometric findings at the end of the course (23) . However, the authors themselves admitted that the results were debatable because of the very low failure rate in the children receiving the antibiotic alone (which left less room to show the efficacy of the adjunctive drug), and because the higher proportion of temporary improvement in tympanometric findings may have reflected the positive effect of corticosteroids on Eustachian tube function, which might have led to a reduced risk of OME with longer administration.
There are three major studies of the impact of steroid treatment on OME, two of which used intranasal mometasone furoate (24, 25) and one intranasal aqueous triamcinolone (26) . The only study that found a significant improvement was that enrolling children with OME and adenoidal hypertrophy, and the benefit was related to a reduction in obstructive symptoms (24) . However, Simpson et aI. have recently published a Cochrane review of the efficacy of oral and topical intranasal steroids, alone or combined with another agent such as an oral antibiotic, in children with OME (27) , and found that there was no evidence that oral or topical steroid treatment offered any benefit in terms of the hearing loss associated with OME. The short-term «1 month) data evaluating OME resolution showed that oral steroids had an effect significantly better than control treatment, and oral steroids plus antibiotic also improved OME outcomes in comparison with placebo plus antibiotic. However, the studies were significantly heterogeneous, and there was no evidence of a beneficial effect on OME resolution after a follow-up of more than one month, and no evidence that oral or topical steroid treatment was beneficial in terms of symptoms.
As no further high-quality studies have been carried out, the effect of oral and topical steroids on AOM and OME is still undefined, and they should not be recommended.
ACUTE PHARINGYTIS (AP)
AP is the cause of about 5% of pediatric medical examinations (28) . Most cases are due to viruses (mainly rhinovirus, coronavirus and adenovirus), whereas Streptococcus pyogenes and Mycoplasma pneumoniae are the most frequently encountered bacterial pathogens (29) . The clinical relevance of viral pharyngitis is marginal because most cases spontaneously resolve in a few days without causing significant sequelae (28) . However, cases caused by 
to complete resolution of sore vs placebo throat S. pyogenes can be followed by severe early and late complications such as peritonsillar abscesses, cervical lymphadenitis, mastoiditis, glomerulonephritis, and rheumatic fever (28) . This explains why all of the international guidelines published by scientific societies recommend the use of antibiotics when a streptococcal etiology is demonstrated or strongly suspected, although there are some differences in patient selection (28) (29) (30) . As all experts consider that M pneumoniae is not a dangerous pathogen, it is therefore usually not sought and consequently remains untreated; however, some data seem to suggest that it can cause recurrences involving both the upper and lower respiratory tract (31) . Regardless of its etiology, AP is usually accompanied by fever and a significant sore throat, and so antipyretics with analgesic effects such as paracetamol and ibuprofen are recommended (28, 30) ; even in streptococcal cases, antibiotics only have a slightly beneficial effect on symptoms and fever (32) . It has been suggested that corticosteroids could offer similar symptomatic relief from sore throat and could be used in the treatment ofAP. Table  III summarises the main clinical trials that have evaluated the effects of combined corticosteroid and antibiotic treatment in patients with AP. Oral dexamethasone was the only steroid used in the three main pediatric studies (33) (34) (35) , two of which found it to be associated with a significantly faster reduction in pain or complete pain relief (34, 35) . However, these studies have some methodological limitations: the population was small and heterogeneous in terms of AP etiology; the mean time to the onset of pain relief and pain resolution seems to be limited by recall bias; and differently efficacious visual methods were used to objectify pain. The advantage of using corticosteroids (i.e. a 4-6 hour reduction in the duration of pain without any change in the number of lost school days) seems to be too slight to justify their universal administration. Furthermore, the risk ofadverse events has never been investigated in long-term studies and, as children can experience repeated episodes of AP during a short period, the administration of corticosteroids can lead to negative effects. Finally, there is no published study of the effects of corticosteroid administration on the development of acute rheumatic fever.
Hayward et al. recently assessed the clinical benefit of corticosteroids observed in randomised controlled trials comparing steroids with placebo or standard care in adults and children aged >3 years with a sore throat (36) . All ofthe trials gave antibiotics to the members of the placebo and corticosteroid groups, and none investigated corticosteroids as a stand-alone treatment. Without differentiating adults and children, they found that corticosteroids more than tripled the likelihood of complete pain resolution after 24 hours, and increased it 1.7 times after 48 hours. Despite the presence of significant heterogeneity, corticosteroids also reduced the mean time to the onset of pain relief by six hours, and the mean time to complete resolution by 14 hours. Nevertheless, the authors concluded that further trials are warranted to assess corticosteroids in the absence of antibiotics and in children.
On the basis of the above, we do not believe that the available data support the use of steroids in children with AP. Their possible positive effects are too slight to justify the use of drugs the potential adverse effects of which (particularly in the case of repeated administrations) have not yet been clearly evaluated.
PERIODIC FEVER, APHTHOUS STOMATITIS, PHARINGYTIS AND CERVICAL ADENITIS (PFAPA)
PFAPA is a syndrome characterised by stomatitis with a cluster ofaphthous lesions, pharyngitis, cervical adenitis and high fever occurring every 30 days (range 15-50) and lasting for four days (range 2-7) (37, 38) . As the etiology ofPFAPA is still unknown, therapy is empiric and it is important to note that PFAPAshould not be misdiagnosed as recurrent upper respiratory tract infections. Case series have been described, and oral corticosteroids seem to be the most effective nonsurgical treatment (37, 38) .
A few years ago, Peridis et al. published a metaanalysis showing evidence that oral corticosteroids are effective in resolving symptoms, although they do not prevent future fever cycles (39) . Tonsillectomy (with or without adenoidectomy) has been found to be effective for long-term symptom resolution, but the comparison of steroids and surgery did not show any statistically significant difference. This means that the most effective non-surgical therapy for PFAPA syndrome is represented by corticosteroids. However, in the case of other fever cycles after their administration, surgery should be considered for long-term resolution ofPFAPA syndrome symptoms.
Further randomized and controlled studies with a suitable follow-up are required in order to clarify the best approach to PFAPA.
CONCLUSIONS
Upper respiratory tract infections are extremely common in children, and topical or systemic steroids are often administrated as adjunctive therapy during the acute phase. However, the evidence in favour of their use is very limited. Although recent guidelines recommend antibiotics and intranasal steroids in cases of acute RS (19) , it is not clear which molecule should be administered or for how long, nor whether the benefits are limited to allergic children. In our opinion, the use of intranasal but not systemic steroids is justified only in children with RS and allergic rhinitis. No high-quality studies on AOM have been carried out, and the results in patients with OME are controversial. Consequently, we think that oral and topical steroids should not be recommended in children with AOM or OME. Some studies have found that oral corticosteroids have positive effects on AP (i.e. a more rapid reduction in throat pain and the possibility of avoiding the need for antibiotics), but these are too slight to justify the use of drugs whose potential adverse effects (particularly in the case of repeated administrations) have not been clearly evaluated. We do not believe that the available data support the use of steroids in children with AP. The data concerning PFAPAare very limited and, although oral corticosteroids appear to be effective in resolving symptoms and could be used as first approach before surgery, they do not seem to prevent future fever cycles. This means that further randomised and controlled studies are required in order to approach upper respiratory tract infections correctly and avoid the risks associated with inappropriate steroid use.
